Florida SB 1092: Reduction of Construction Contracting Fraud

Bill Text

1092 
Podiatric Medicine 
2026-03-18T10:43:47Z 
Requiring certain podiatric physicians, instead of all podiatric physicians, to complete specified continuing education; authorizing podiatric physicians to perform procedures using cellular or tissue-based products not approved by the United States Food and Drug Administration under certain circumstances; specifying requirements for the cellular or tissue-based products that may be used by such podiatric physicians; requiring podiatric physicians to obtain a signed consent form from the patient or his or her representative before performing procedures using cellular or tissue-based products, etc. 
ENROLLED 
2026 
S 
2026-06-11T00:00:00Z 
GB 
General Bill 
er 

 ENROLLED 
 2026 Legislature CS for CS for SB 1092 

 20261092er 
 1 
 2 An act relating to podiatric medicine; amending s. 
 3 461.007, F.S.; requiring certain podiatric physicians, 
 4 instead of all podiatric physicians, to complete 
 5 specified continuing education; creating s. 461.011, 
 6 F.S.; providing legislative findings and intent; 
 7 defining terms; authorizing podiatric physicians to 
 8 perform procedures using cellular or tissue-based 
 9 products not approved by the United States Food and 
 10 Drug Administration under certain circumstances; 
 11 specifying requirements for the cellular or tissue 
 12 based products that may be used by such podiatric 
 13 physicians; requiring such podiatric physicians to 
 14 include a specified notice in any form of 
 15 advertisement; specifying requirements for such 
 16 notice; requiring podiatric physicians to obtain a 
 17 signed consent form from the patient or his or her 
 18 representative before performing procedures using 
 19 cellular or tissue-based products; specifying 
 20 requirements for the consent form; providing 
 21 applicability; providing for disciplinary action; 
 22 providing criminal penalties; authorizing the Board of 
 23 Podiatric Medicine to adopt rules; providing an 
 24 effective date. 
 25 
 26 Be It Enacted by the Legislature of the State of Florida: 
 27 
 28 Section 1. Subsection (3) of section 461.007, Florida 
 29 Statutes, is amended to read: 
 30 461.007 Renewal of license.— 
 31 (3) The board may by rule prescribe continuing education, 
 32 not to exceed 40 hours biennially, as a condition for renewal of 
 33 a license, with a minimum of 2 hours of continuing education 
 34 related to the safe and effective prescribing of controlled 
 35 substances for licensees who are registered with the United 
 36 States Drug Enforcement Administration and authorized to 
 37 prescribe controlled substance pursuant to 21 U.S.C. s. 822. The 
 38 criteria for such programs or courses shall be approved by the 
 39 board. 
 40 Section 2. Section 461.011, Florida Statutes, is created to 
 41 read: 
 42 461.011 Cellular and tissue-based products.— 
 43 (1) The Legislature recognizes the significant potential of 
 44 cellular and tissue-based products in advancing medical 
 45 treatments and improving patient outcomes and further recognizes 
 46 the need to ensure that such treatments are provided using 
 47 cellular or tissue-based products obtained in an ethical manner 
 48 that does not involve cells derived from aborted fetuses. It is 
 49 the intent of the Legislature to foster medical innovation while 
 50 upholding ethical standards that respect the sanctity of life. 
 51 By encouraging the use of cellular or tissue-based products, the 
 52 state will advance regenerative medicine in a manner consistent 
 53 with the values of the state. 
 54 (2) As used in this section, the term: 
 55 (a) “Cellular or tissue-based products” means products 
 56 containing or consisting of human cells or tissues which are 
 57 intended for implantation, transplantation, infusion, or 
 58 transfer into a human recipient. The term does not include: 
 59 1. Vascularized human organs for transplantation; 
 60 2. Whole blood or blood components or blood derivative 
 61 products; 
 62 3. Secreted or extracted human products, such as milk, 
 63 collagen, and cell factors, other than semen; 
 64 4. Minimally manipulated bone marrow for homologous use and 
 65 not combined with another article other than water, 
 66 crystalloids, or a sterilizing, preserving, or storage agent, if 
 67 the addition of the agent does not raise new clinical safety 
 68 concerns with respect to the bone marrow; 
 69 5. Ancillary products used in the manufacture of human 
 70 cells, tissues, or cellular or tissue-based products; 
 71 6. Cells, tissues, and organs derived from animals; 
 72 7. In vitro diagnostic products; 
 73 8. Blood vessels recovered with an organ which are intended 
 74 for use in organ transplantation and labeled “For use in organ 
 75 transplantation only”; or 
 76 9. Harvesting and reimplantation of autologous tissue. 
 77 (b) “Minimally manipulated” means: 
 78 1. For structural tissue, processing that does not alter 
 79 the original relevant char